حصرياً
Release Date
Prof. Dr. Konstanze Döhner - The Practicalities of Personalised Therapy in AML: The Who, How, When, and Why of Treating IDH1-Mutated Disease
Karen C. Daily, D.O. - RiskReady: A Systems Approach to Improving the Recognition and Treatment of High-Risk, HR+, HER2- Early Breast Cancer
Lynsey P. Teulings, APRN - Ahead of the Immunotherapy Curve in Head and Neck Cancer: Preparing for Expanding Immune Options in Locally Advanced and Recurrent/Metastatic Disease
Susana Banerjee, MBBS, MA, FRCP, PhD, Ana Oaknin, MD, PhD - Putting the Puzzle Together in Advanced Ovarian and Cervical Cancers: Translating Evidence Into Practice for Approved and Emerging ADCs
Professor Stephen Johnston, MA, FRCP, PhD - Charting New Paths in the Treatment of ER+, HER2- MBC: Seeking Clarity and Consensus Through Evidence-Aligned Clinical Cases